ArticleBreast cancer research and treatment2017
Screening-relevant age threshold of 70 years and older is a stronger determinant for the choice of adjuvant treatment in breast cancer patients than tumor biology.
Article in Breast cancer research and treatment, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Chemotherapy in elderly patients with early breast cancer: a systematic review.Archives of gynecology and obstetrics · 2025Pooled it
- Geriatric Breast Cancer: Staging, Molecular Surrogates, and Treatment. A Review & Meta-analysis.Aging and disease · 2024Pooled it
- Treatment Patterns, Trends, and Outcomes of Neoadjuvant Chemotherapy Use Among Patients With Early-Stage Invasive Triple-Negative Breast Cancer.JCO oncology practice · 2025Article
- The association between poor dental health and gastric cancer risk: a nationwide cohort and sibling-controlled study.BMC medicine · 2025Article
- Clinical, therapeutic and prognostic differences between male and female patients with breast cancer-a comparison of 2510 men and 307,634 women in a registry-based study in Germany.Journal of cancer research and clinical oncology · 2025Article
- Are there differences in overall survival among older breast cancer patients by race and ethnicity?Surgery · 2025Article
- Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers.Journal of cancer research and clinical oncology · 2023Article
- COVID-19 Incidence and Mortality in Patients Operated on for Breast Cancer. Comparison with the General Population.Clinical breast cancer · 2023Article
- Prognostic role of radiotherapy in low-risk elderly breast cancer patients after breast-conserving surgery: a cohort study.Gland surgery · 2022Article
- Chemotherapy Decision-Making and Survival Outcomes in Older Women With Early Triple-Negative Breast Cancer: Evidence From Real-World Practice.Frontiers in oncology · 2022Article
- Suboptimal therapy following breast conserving surgery in triple-negative and HER2-positive breast cancer patients.Breast cancer research and treatment · 2021Article
- Defining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature Review.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Article
- Breast Cancer and COVID-19: The Effect of Fear on Patients' Decision-making Process.In vivo (Athens, Greece) · 2020Article
- Aberrant methylation of WD-repeat protein 41 contributes to tumour progression in triple-negative breast cancer.Journal of cellular and molecular medicine · 2020Article
- Symptom Experience, Management, and Outcomes According to Race and Social Determinants Including Genomics, Epigenomics, and Metabolomics (SEMOARS + GEM): an Explanatory Model for Breast Cancer Treatment Disparity.Journal of cancer education : the official journal of the American Association for Cancer Education · 2020Article
- Guideline-concordant chemotherapy in patients with hormone receptor-positive and node-positive, early breast cancer leads to better overall and metastases-free survival with limited benefit in elderly patients.Archives of gynecology and obstetrics · 2020Article
- Association of Axillary Lymph Node Evaluation With Survival in Women Aged 70 Years or Older With Breast Cancer.Frontiers in oncology · 2020Article
- Receipt of Guideline-Concordant Care Among Older Women With Stage I-III Breast Cancer: A Population-Based Study.Journal of the National Comprehensive Cancer Network : JNCCN · 2018Article
- Long intergenic non-protein coding RNA 1006 used as a potential novel biomarker of gastric cancer.Cancer biomarkers : section A of Disease markers · 2017Article
- Does Age Matter? Estimating Risks of Locoregional Recurrence After Breast-conservative Surgery.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe 70-year threshold determines whether patients are eligible or not for the breast cancer screening program in Germany. It is not known whether this age threshold also influences the choice of adjuvant treatment and ultimate outcome.
methods3463 patients were analyzed from the clinical cancer registry Regensburg (Germany) with primary, non-metastatic invasive breast cancer diagnosed between 2000 and 2012. The distribution of tumor biological subtypes was evaluated in breast cancer patients both in those eligible for screening (ESG, 50-69 years) and those not eligible for screening (NESG, ≥70 years). Local and systemic therapies in different subtypes as well as overall survival (OS) were analyzed.
results2171 patients (62.7%) pertained to the ESG and 1292 patients (37.3%) referred to the NESG. The distribution of the common subtypes Luminal A, Luminal B, HER2-like, and Basal-like was comparable in both groups. Treatment varied considerably with less systemic therapies in all subtypes in patients in the NESG. Regarding local therapies, patients in the NESG also received less surgery and less radiotherapy. As to Luminal A patients, best OS was seen in patients receiving endocrine therapy (ET) (7-year OS of 95.6%) and CHT plus ET (7-year OS of 93.1%) in the ESG. In the NESG, best OS was seen in patients receiving CHT plus ET (7-year OS of 95.2%), whereas patients receiving only ET had a 7-year OS of 73.9%.
conclusionsDespite similar tumor biology, elderly patients are undertreated regarding both systemic and local therapies compared to younger patients, leading to reduced OS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.